Abbott's strong second quarter, with significant growth across all four major businesses, comes as the tempo of everyday life in some parts of the world is returning to normal: workplaces reopening, sporting events resuming and travelers taking to the skies. For the quarter, Abbott's worldwide sales of $10.2 billion climbed 35% on an organic* basis, 39.5% reported. Notably, when comparing Abbott’s sales to pre-pandemic levels — and excluding COVID-19 testing-related sales — the company saw strong growth of 11.3% organic (12.3% reported) versus the second quarter of 2019.1 Abbott's adjusted diluted earnings per share (EPS) was $1.17, reflecting 105.3% growth compared to the prior year.2 This momentum highlights the strength of Abbott’s diversified product pipeline, as the company's businesses that performed well throughout the pandemic continue to see great success and businesses that were negatively impacted by COVID-19 are growing at — or above — pre-pandemic levels. Given this solid performance, Abbott continues to forecast strong double-digit earnings growth compared to the prior year. Some of the key second-quarter highlights: Significant growth in Medical Devices — 45.1% organic (51.3% reported) — was driven by continued strong recovery from the COVID-19 pandemic. A key growth driver for the quarter: Diabetes Care's $904 million in sales of Abbott's FreeStyle Libre technology. The FreeStyle Libre system now has more than 3 million users worldwide.3 Compared to 2019, Medical Devices sales increased 15.6% organic (19.2% reported), led by double-digit growth in Electrophysiology, Heart Failure, Structural Heart and Diabetes Care.4 Strong Diagnostics sales — up 57.2% organic (62.8% reported) — includes $1.3 billion in global COVID-19 testing sales in the quarter. Sales in Core Laboratory and Molecular Diagnostics, excluding COVID-19 testing-related sales, grew 4.2% and 6.5%, respectively, on an organic basis and 6.8% and 8.3%, respectively, on a reported basis.5 Solid growth in Nutrition — 9.5% organic (11.9% reported) — was spurred by demand for Abbott’s Adult Nutrition products, led by Ensure (Abbott’s market-leading nutrition brand) and Glucerna (Abbott's best-in-class diabetes nutrition product), as well as U.S. growth of Pedialyte, (the company's oral rehydration brand) and PediaSure (Abbott's complete, balanced nutrition brand for children). New approvals and announcements in the quarter added more momentum to Abbott's already strong portfolio of life-changing technologies. This includes CE Mark in Europe in May for Navitor, Abbott's latest-generation transcatheter aortic valve implantation system for the treatment of aortic stenosis, which has new advancements designed to prevent blood leakage around the implant. Abbott released new data in June showing FreeStyle Libre achieves meaningful health benefits and is accessible to a greater population of people with diabetes, compared to other competitor continuous glucose monitor systems. The company also received European and U.S. regulatory approval for its next-generation XIENCE Skypoint stent and new labeling that expands access of the XIENCE family of stents to more patients. For full financials and reconciliation of non-GAAP measures, you can read Abbott's press release. For further information, take a look at some additional materials below: Abbott President and CEO Robert Ford shared his views on our pipeline and how our technologies help people live fuller, healthier lives.